GLP-1 Therapy Linked to 41 Percent Lower Risk of Obesity-Related Cancers: Study
Taiwan: In a large propensity-matched cohort study, patients receiving GLP-1 receptor agonists for obesity experienced a 41% lower risk of obesity-associated cancers compared with those managed with diet and exercise alone. Among GLP-1–based therapies, tirzepatide was associated with a substantially greater reduction in cancer risk than semaglutide.
These findings add to a growing body of evidence suggesting that GLP-1–targeted treatments may provide benefits beyond weight loss and glycemic control, potentially contributing to a lower risk of obesity-related malignancies. However, further long-term studies are needed to confirm these observational findings and clarify underlying mechanisms.
The findings were published in Annals of Oncology by A.H.-C. Hsu from the Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan, and colleagues.
As obesity-related cancers continue to rise worldwide, interest has grown in whether GLP-1 receptor agonists may offer benefits beyond weight loss. To investigate this, researchers examined the association between GLP-1RA use and obesity-associated cancer risk in obese adults without diabetes.
Using data from the TriNetX database, which includes records from approximately 113 million patients in the United States, the investigators conducted a target trial emulation involving obese, nondiabetic adults with no prior history of obesity-associated cancer between December 2014 and June 2025.
After propensity score matching, the study included 161,798 participants, comprising 80,899 GLP-1RA users and 80,899 matched individuals who received diet or exercise counseling alone. The mean age was 47.2 years, and the median follow-up period was two years.
Key Findings:
- GLP-1 receptor agonist use was associated with a significantly lower incidence of obesity-associated cancers compared with diet and exercise counseling alone.
- Patients receiving GLP-1 receptor agonists had a 41% lower risk of developing any obesity-associated cancer during follow-up.
- The reduced cancer risk associated with GLP-1 receptor agonist use was observed across most patient subgroups evaluated.
- The protective association was seen in both men and women and among individuals with different levels of obesity.
- The association between GLP-1 receptor agonist use and lower cancer risk was not consistently observed among Black participants.
- Additional analyses using inverse probability of treatment weighting confirmed the primary findings, supporting the robustness of the results.
The study is the first to specifically evaluate the association between GLP-1 receptor agonist use and obesity-associated cancer risk in obese adults without diabetes, addressing a gap left by earlier studies that primarily involved diabetic or mixed populations.
The authors concluded that GLP-1RA therapy was associated with a significantly lower short-term incidence of obesity-associated cancers in obese, nondiabetic adults. However, given the observational nature of the study and the median follow-up of only two years, they cautioned that causality cannot be established. Further prospective studies with longer follow-up are needed to confirm these findings and clarify the underlying mechanisms.
Reference:
Hsu, A., Ramirez, P., Chang, Y., Chiang, Y., Santía, M., Meschini, T., Mateo-Kubach, P., Suri, A., & Kamat, A. (2026). GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults. Annals of Oncology. https://doi.org/10.1016/j.annonc.2026.04.013
Next Story